Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dabogratinib (TYRA-300) 60mg
Dabogratinib · 1 trial · 1 indication
Complete response (CR) rate
| Arm | Type | Description |
|---|---|---|
| Study Drug Dose Cohort A (DCA) 60mg | EXPERIMENTAL | Dabogratinib (TYRA-300) monotherapy in Participants |
| Study Drug Dose Cohort B (DCB) 80mg | EXPERIMENTAL | Dabogratinib (TYRA-300) monotherapy in Participants |
| Possible Study Drug Dose Cohort C (DCC) TBD mg | EXPERIMENTAL | Dabogratinib (TYRA-300) monotherapy in Participants |
| Name | Type | Description |
|---|---|---|
| Dabogratinib (TYRA-300) 60mg | DRUG | Self-administered 60mg dose Oral tablet(s) given daily |
| Dabogratinib (TYRA-300) 80mg | DRUG | Self-administered 80mg dose Oral tablet(s) given daily |
| Dabogratinib (TYRA-300) TBD | DRUG | To be determined: Self-administered Oral tablet(s) given daily |
1. Participants ≥ 18 years of age at the time of informed consent and willing and able to comply with all required study procedures 2. Confirmed LOW RISK LG UTUC (both favorable and unfavorable) per AUA 3. At least 5mm of marker lesion left behind 4. Participants must have previous genomic report or...
Dabogratinib is an investigational small molecule being studied for the treatment of Low Grade Upper Tract Urothelial Carcinoma, a type of cancer affecting the upper urinary tract. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Dabogratinib is a kinase inhibitor, a class of drugs that work by blocking specific enzymes involved in cell signaling and growth. Its exact molecular target has not been disclosed, but as a -tinib, it is designed to interfere with kinase activity relevant to cancer cell proliferation.
Dabogratinib is being developed by Tyra Biosciences, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol TYRA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Low Grade Upper Tract Urothelial Carcinoma.
Dabogratinib is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received approval from the FDA or other regulatory bodies. The ongoing Phase 2 trial is designed to assess its efficacy and safety in the target patient population.
Dabogratinib is being evaluated in a Phase 2A/B clinical trial registered as NCT07265947. This study is recruiting participants with Low Grade Upper Tract Urothelial Carcinoma and aims to enroll approximately 230 patients across sites in the United States and Spain. The trial is controlled but not blinded.
Yes, Dabogratinib is also known as TYRA-300, specifically in its 60mg formulation. The drug is being developed under this alternative name in clinical and research contexts, and both names refer to the same investigational compound.